Neurocrine Biosciences IncNBIX
ASignal's systematic analysis rates NBIX as Bullish.
Reflects the latest available analysis · analyzed Aug 30, 2026
The case on NBIX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (39.5% YoY)
- High gross margin (64.48%) indicating pricing power
- Exceptional return on equity (22.09%)
- Low debt-to-equity ratio (0.12x) reflecting strong financial health
- Free cash flow of $638.24M supports operational strength
- Forward P/E of 12.89x below current P/E, suggesting earnings growth expectations
- Negative MACD (-3.84) below signal line (-4.01), signaling bearish momentum
- Price below both SMA20 and SMA50, indicating short- and medium-term downtrend
- Price momentum slightly negative (-0.0028)
- No Reddit mentions, suggesting limited retail investor interest or visibility
See the full verdict on NBIX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NBIX
Most investors never get a second opinion, let alone several. ASignal runs NBIX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.